Evidence map›Paper›PMID 35694350›Full record

ArticleChemical science2022

Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe.

Thais Gazzi, Benjamin Brennecke, Kenneth Atz, Claudia Korn, David Sykes, Gabriel Forn-Cuni, Patrick Pfaff, Roman C Sarott, Matthias V Westphal, Yelena Mostinski and 47 more

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Chemical Probes for Investigating the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  4. Probing Native CBChembiochem : a European journal of chemical biology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Rational Design, Synthesis, and Evaluation of Fluorescent CBPharmaceuticals (Basel, Switzerland) · 2023
    Review
  12. Article
  13. Special issue for Klaus Gawrisch.Biophysical journal · 2023
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors at 14 institutions in 8 countries.

Thais GazziLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Benjamin BrenneckeLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Kenneth AtzRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Claudia KornRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
David SykesFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Gabriel Forn-CuniLeiden University Einsteinweg 55 2333 CC Leiden the Netherlands.
Patrick PfaffLaboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich Vladimir-Prelog-Weg 3 8093 Zürich Switzerland.
Roman C SarottLaboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich Vladimir-Prelog-Weg 3 8093 Zürich Switzerland.ORCID https://orcid.org/0000-0001-8789-6150
Matthias V WestphalLaboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich Vladimir-Prelog-Weg 3 8093 Zürich Switzerland.
Yelena MostinskiLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Leonard MachLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Malgorzata Wasinska-KalwaLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Marie WeiseLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Bradley L HoareFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Tamara MiljušFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Maira MexiFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Nicolas RothWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London EC1M 6BQ England UK.
Eline J KoersFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Wolfgang GubaRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
André AlkerRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Arne C RuferRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Eric A KusznirRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Sylwia HuberRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Catarina RaposoRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Elisabeth A ZirwesRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Anja OsterwaldRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Anto PavlovicRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Svenja MoesRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Jennifer BeckRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Matthias NettekovenRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Irene Benito-CuestaFaculty of Experimental Sciences, Universidad Francisco de Vitoria Pozuelo de Alarcón 28223 Madrid Spain.
Teresa GrandeFaculty of Experimental Sciences, Universidad Francisco de Vitoria Pozuelo de Alarcón 28223 Madrid Spain.
Faye DrawnelRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Gabriella WidmerRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Daniela HolzerRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Tom van der WelDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University 2333 CC Leiden the Netherlands.
Harpreet MandhairInstitute of Biochemistry and Molecular Medicine, University of Bern 3012 Bern Switzerland.ORCID https://orcid.org/0000-0001-8753-7078
Michael HonerRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Jürgen FingerleRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Jörg ScheffelDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin Berlin Germany.
Johannes BroichhagenLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.ORCID https://orcid.org/0000-0003-3084-6595
Klaus GawrischNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Rockville MD 20852 USA.
Julián RomeroFaculty of Experimental Sciences, Universidad Francisco de Vitoria Pozuelo de Alarcón 28223 Madrid Spain.
Cecilia J HillardDepartment of Pharmacology and Toxicology, Neuroscience Research Center, Medical College of Wisconsin Milwaukee WI 53226 USA.
Zoltan V VargaNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Rockville MD 20852 USA.
Mario van der SteltDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University 2333 CC Leiden the Netherlands.
Pal PacherNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Rockville MD 20852 USA.
Jürg GertschInstitute of Biochemistry and Molecular Medicine, University of Bern 3012 Bern Switzerland.
Christoph UllmerRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Peter J McCormickWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London EC1M 6BQ England UK.
Sergio OddiFaculty of Veterinary Medicine, University of Teramo 64100 Teramo European Italy.
Herman P SpainkLeiden University Einsteinweg 55 2333 CC Leiden the Netherlands.ORCID https://orcid.org/0000-0003-4128-9501
Mauro MaccarroneEuropean Center for Brain Research (CERC), Santa Lucia Foundation 00179 Rome Italy.
Dmitry B VeprintsevFaculty of Medicine & Health Sciences, University of Nottingham Nottingham NG7 2UH England UK.
Erick M CarreiraLaboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich Vladimir-Prelog-Weg 3 8093 Zürich Switzerland.
Uwe GretherRoche Pharma Research & Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland uwe.grether@roche.com.
Marc NazaréLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.ORCID https://orcid.org/0000-0002-1602-2330
Roche (Switzerland) · CHLeibniz-Forschungsinstitut für Molekulare Pharmakologie · DEUniversity of Nottingham · GBETH Zurich · CHLeiden University · NLUniversidad Francisco de Vitoria · ESNational Institutes of Health · USQueen Mary University of London · GBUniversity of Bern · CHHumboldt-Universität zu Berlin · DEMedical College of Wisconsin · USSemmelweis University · HUUniversity of L'Aquila · ITUniversity of Teramo · IT

Funding

Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injuryZIAAA000375 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI PACHER, PAL · 2009 to 2025
$27.8M
6 · The paper itself

Abstract

Despite its essential role in the (patho)physiology of several diseases, CB

Identifiers

PMID35694350
PMCPMC9116301
OpenAlexW4226210071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.